Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 743 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Peripheral Arterial Disease Clear all

Conditions: Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
Interventions: melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization; Drug · Procedure
Lead sponsor: Delcath Systems Inc.; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 12
States / cities: Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more

Conditions: Peripheral Artery Disease
Interventions: Home-based exercise intervention; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Chicago, Illinois • Minneapolis, Minnesota • New York, New York

Conditions: Critical Limb Ischemia
Interventions: Not listed
Lead sponsor: HyperMed; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Critical Limb Ischemia
Interventions: care as usual; Other
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: New Haven, Connecticut • Cleveland, Ohio

Conditions: Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia
Interventions: Actionable remotely generated health data, Non-Actionable remotely generated health data; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 60 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Peripheral Arterial Disease, Claudication, Critical Limb Ischemia
Interventions: Atherectomy; Device
Lead sponsor: Volcano Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Tucson, Arizona • Detroit, Michigan • Saginaw, Michigan + 2 more

Conditions: Peripheral Arterial Disease
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Chicago, Illinois

Conditions: Peripheral Arterial Disease
Interventions: Ischemic preconditioning, Control; Other
Lead sponsor: Center for Veterans Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg, Thrombus in the Peripheral Venous Vasculature, Peripheral Arterial Disease, Acute Limb Ischemia, Lower Extremity Acute Limb Ischemia, LE ALI
Interventions: Liberant Thrombectomy System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 22 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 6
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Naples, Florida + 3 more

Conditions: Cardiovascular Diseases, Peripheral Vascular Diseases
Interventions: Exercise, Diet; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
Interventions: Supira System; Device
Lead sponsor: Supira Medical; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Sacramento, California • Atlanta, Georgia • New York, New York + 1 more

Conditions: Peripheral Arterial Disease, Intermittent Claudication
Interventions: Intermittent compression; Device
Lead sponsor: FlowMedic; Industry
Eligibility: 40 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Jacksonville, Florida • San Antonio, Texas

Conditions: Intermittent Claudication
Interventions: K-134, Cilostazol 100 mg BID, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 30
States / cities: Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more

Conditions: Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions: Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Salem, Massachusetts

Conditions: Intermittent Claudication, Peripheral Artery Disease
Interventions: Placebo, 375 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 40 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more

Conditions: Peripheral Vascular Diseases, Arterial Occlusive Diseases, Ischemia, Graft Occlusion, Vascular, Hyperplasia
Interventions: CGT003 (E2F Duplex Decoy); Drug
Lead sponsor: Anesiva, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 116
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more

Conditions: Peripheral Artery Disease, Diabetes Mellitus, Chronic Limb-Threatening Ischemia
Interventions: SPECT/CT perfusion imaging, PET/CT perfusion imaging; Diagnostic Test
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prevention & Control
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 27,395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 53
States / cities: Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more

Conditions: Atherosclerosis, Healthy
Interventions: [C-11]PBR28; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 89 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 204
States / cities: Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more

Conditions: Peripheral Arterial Disease
Interventions: Tack Endovascular System; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 37
States / cities: Yuma, Arizona • Fremont, California • Denver, Colorado + 33 more

Conditions: Coronary Artery Disease
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Peripheral Artery Disease, Peripheral Vascular Diseases, Peripheral Arterial Disease, Peripheral Arterial Occlusive Disease
Interventions: Vumerity, Placebo; Drug · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Critical Limb Ischemia
Interventions: Cord blood stem cell injection; Biological
Lead sponsor: Richard Burt, MD; Other
Eligibility: 18 Years to 72 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Patient Centered Home Exercise Program for Peripheral Artery Disease

Validation of OxyVu for Assessing Level of Amputation With Comparison to Other Modalities

SCOPE CLI (Shifting Care and Outcomes for Patients With Endangered Limbs - Critical Limb Ischemia)

The ROAMM-EHR Study

Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems

BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients

Cardiac Remote Ischemic Preconditioning Before Elective Major Vascular Surgery

Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

Improving Functioning in Peripheral Arterial Disease

Early Feasibility Study of the Supira System in Patients Undergoing HRPCI

Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)

Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee Arteries

Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention

Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia